WO1999018220A1 - Papilloma virus capsomere vaccine formulations and methods of use - Google Patents
Papilloma virus capsomere vaccine formulations and methods of use Download PDFInfo
- Publication number
- WO1999018220A1 WO1999018220A1 PCT/US1998/020965 US9820965W WO9918220A1 WO 1999018220 A1 WO1999018220 A1 WO 1999018220A1 US 9820965 W US9820965 W US 9820965W WO 9918220 A1 WO9918220 A1 WO 9918220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- hpv
- leu
- amino acid
- seq
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000009472 formulation Methods 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 23
- 241001631646 Papillomaviridae Species 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 138
- 102000004169 proteins and genes Human genes 0.000 claims description 131
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 75
- 125000000539 amino acid group Chemical group 0.000 claims description 49
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 102000037865 fusion proteins Human genes 0.000 claims description 33
- 108020001507 fusion proteins Proteins 0.000 claims description 33
- 208000003154 papilloma Diseases 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 17
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000000069 prophylactic effect Effects 0.000 abstract description 9
- 230000003612 virological effect Effects 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 111
- 108020004414 DNA Proteins 0.000 description 58
- 235000001014 amino acid Nutrition 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 108010067390 Viral Proteins Proteins 0.000 description 20
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 235000004252 protein component Nutrition 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 206010008263 Cervical dysplasia Diseases 0.000 description 6
- 108010065920 Insulin Lispro Proteins 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 208000019065 cervical carcinoma Diseases 0.000 description 6
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 108010034529 leucyl-lysine Proteins 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- HLZORBMOISUNIV-DCAQKATOSA-N Met-Ser-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C HLZORBMOISUNIV-DCAQKATOSA-N 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000011536 extraction buffer Substances 0.000 description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 4
- 108010050848 glycylleucine Proteins 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- 206010061978 Genital lesion Diseases 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 2
- NXSFUECZFORGOG-CIUDSAMLSA-N Ala-Asn-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXSFUECZFORGOG-CIUDSAMLSA-N 0.000 description 2
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 2
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 2
- JQDFGZKKXBEANU-IMJSIDKUSA-N Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(O)=O JQDFGZKKXBEANU-IMJSIDKUSA-N 0.000 description 2
- MIPWEZAIMPYQST-FXQIFTODSA-N Ala-Cys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O MIPWEZAIMPYQST-FXQIFTODSA-N 0.000 description 2
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 2
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 2
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 2
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 2
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 2
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 2
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 2
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 2
- YFWTXMRJJDNTLM-LSJOCFKGSA-N Arg-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFWTXMRJJDNTLM-LSJOCFKGSA-N 0.000 description 2
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 2
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 2
- MSILNNHVVMMTHZ-UWVGGRQHSA-N Arg-His-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 MSILNNHVVMMTHZ-UWVGGRQHSA-N 0.000 description 2
- NIUDXSFNLBIWOB-DCAQKATOSA-N Arg-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NIUDXSFNLBIWOB-DCAQKATOSA-N 0.000 description 2
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 2
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 2
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 2
- HZPSDHRYYIORKR-WHFBIAKZSA-N Asn-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O HZPSDHRYYIORKR-WHFBIAKZSA-N 0.000 description 2
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 2
- GURLOFOJBHRPJN-AAEUAGOBSA-N Asn-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N GURLOFOJBHRPJN-AAEUAGOBSA-N 0.000 description 2
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 2
- WXVGISRWSYGEDK-KKUMJFAQSA-N Asn-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N WXVGISRWSYGEDK-KKUMJFAQSA-N 0.000 description 2
- RVHGJNGNKGDCPX-KKUMJFAQSA-N Asn-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N RVHGJNGNKGDCPX-KKUMJFAQSA-N 0.000 description 2
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 2
- CBWCQCANJSGUOH-ZKWXMUAHSA-N Asn-Val-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O CBWCQCANJSGUOH-ZKWXMUAHSA-N 0.000 description 2
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 2
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 2
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 2
- PAYPSKIBMDHZPI-CIUDSAMLSA-N Asp-Leu-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PAYPSKIBMDHZPI-CIUDSAMLSA-N 0.000 description 2
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 2
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 2
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 2
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 2
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 2
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 2
- NVXLFIPTHPKSKL-UBHSHLNASA-N Asp-Trp-Asn Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(O)=O)N)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 NVXLFIPTHPKSKL-UBHSHLNASA-N 0.000 description 2
- WAEDSQFVZJUHLI-BYULHYEWSA-N Asp-Val-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WAEDSQFVZJUHLI-BYULHYEWSA-N 0.000 description 2
- XQFLFQWOBXPMHW-NHCYSSNCSA-N Asp-Val-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XQFLFQWOBXPMHW-NHCYSSNCSA-N 0.000 description 2
- VDUPGIDTWNQAJD-CIUDSAMLSA-N Cys-Lys-Cys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(O)=O VDUPGIDTWNQAJD-CIUDSAMLSA-N 0.000 description 2
- XMVZMBGFIOQONW-GARJFASQSA-N Cys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)C(=O)O XMVZMBGFIOQONW-GARJFASQSA-N 0.000 description 2
- JUUMIGUJJRFQQR-KKUMJFAQSA-N Cys-Lys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)O JUUMIGUJJRFQQR-KKUMJFAQSA-N 0.000 description 2
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 2
- WTXCNOPZMQRTNN-BWBBJGPYSA-N Cys-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)O WTXCNOPZMQRTNN-BWBBJGPYSA-N 0.000 description 2
- BUAUGQJXGNRTQE-AAEUAGOBSA-N Cys-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N BUAUGQJXGNRTQE-AAEUAGOBSA-N 0.000 description 2
- PCBBLFVHTYNQGG-LAEOZQHASA-N Glu-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N PCBBLFVHTYNQGG-LAEOZQHASA-N 0.000 description 2
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 2
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 2
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 2
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 2
- HHSKZJZWQFPSKN-AVGNSLFASA-N Glu-Tyr-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O HHSKZJZWQFPSKN-AVGNSLFASA-N 0.000 description 2
- UUTGYDAKPISJAO-JYJNAYRXSA-N Glu-Tyr-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 UUTGYDAKPISJAO-JYJNAYRXSA-N 0.000 description 2
- QEJKKJNDDDPSMU-KKUMJFAQSA-N Glu-Tyr-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(O)=O QEJKKJNDDDPSMU-KKUMJFAQSA-N 0.000 description 2
- HBMRTXJZQDVRFT-DZKIICNBSA-N Glu-Tyr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HBMRTXJZQDVRFT-DZKIICNBSA-N 0.000 description 2
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 2
- KFMBRBPXHVMDFN-UWVGGRQHSA-N Gly-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCNC(N)=N KFMBRBPXHVMDFN-UWVGGRQHSA-N 0.000 description 2
- SUDUYJOBLHQAMI-WHFBIAKZSA-N Gly-Asp-Cys Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O SUDUYJOBLHQAMI-WHFBIAKZSA-N 0.000 description 2
- JUBDONGMHASUCN-IUCAKERBSA-N Gly-Glu-His Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O JUBDONGMHASUCN-IUCAKERBSA-N 0.000 description 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 2
- AYBKPDHHVADEDA-YUMQZZPRSA-N Gly-His-Asn Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O AYBKPDHHVADEDA-YUMQZZPRSA-N 0.000 description 2
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 2
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 2
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 2
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 2
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- SKOKHBGDXGTDDP-MELADBBJSA-N His-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N SKOKHBGDXGTDDP-MELADBBJSA-N 0.000 description 2
- BFOGZWSSGMLYKV-DCAQKATOSA-N His-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N BFOGZWSSGMLYKV-DCAQKATOSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 2
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 2
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 2
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 2
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 2
- NHHKSOGJYNQENP-SRVKXCTJSA-N Leu-Cys-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N NHHKSOGJYNQENP-SRVKXCTJSA-N 0.000 description 2
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 2
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 2
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 2
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 2
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 2
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 2
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 description 2
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 2
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 2
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 2
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 2
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 2
- NTXYXFDMIHXTHE-WDSOQIARSA-N Leu-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 NTXYXFDMIHXTHE-WDSOQIARSA-N 0.000 description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 2
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 2
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 2
- QBGPXOGXCVKULO-BQBZGAKWSA-N Lys-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(O)=O QBGPXOGXCVKULO-BQBZGAKWSA-N 0.000 description 2
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 2
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 2
- HQXSFFSLXFHWOX-IXOXFDKPSA-N Lys-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N)O HQXSFFSLXFHWOX-IXOXFDKPSA-N 0.000 description 2
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 2
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 description 2
- KFSALEZVQJYHCE-AVGNSLFASA-N Lys-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N KFSALEZVQJYHCE-AVGNSLFASA-N 0.000 description 2
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 2
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 2
- SXWQMBGNFXAGAT-FJXKBIBVSA-N Met-Gly-Thr Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SXWQMBGNFXAGAT-FJXKBIBVSA-N 0.000 description 2
- WXJXYMFUTRXRGO-UWVGGRQHSA-N Met-His-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CNC=N1 WXJXYMFUTRXRGO-UWVGGRQHSA-N 0.000 description 2
- HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 2
- NSMXRFMGZYTFEX-KJEVXHAQSA-N Met-Thr-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCSC)N)O NSMXRFMGZYTFEX-KJEVXHAQSA-N 0.000 description 2
- OVTOTTGZBWXLFU-QXEWZRGKSA-N Met-Val-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O OVTOTTGZBWXLFU-QXEWZRGKSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 2
- APJPXSFJBMMOLW-KBPBESRZSA-N Phe-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 APJPXSFJBMMOLW-KBPBESRZSA-N 0.000 description 2
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 2
- DSXPMZMSJHOKKK-HJOGWXRNSA-N Phe-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DSXPMZMSJHOKKK-HJOGWXRNSA-N 0.000 description 2
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 2
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 2
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 2
- VFDRDMOMHBJGKD-UFYCRDLUSA-N Phe-Tyr-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N VFDRDMOMHBJGKD-UFYCRDLUSA-N 0.000 description 2
- GTMSCDVFQLNEOY-BZSNNMDCSA-N Phe-Tyr-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N GTMSCDVFQLNEOY-BZSNNMDCSA-N 0.000 description 2
- GOUWCZRDTWTODO-YDHLFZDLSA-N Phe-Val-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O GOUWCZRDTWTODO-YDHLFZDLSA-N 0.000 description 2
- MWQXFDIQXIXPMS-UNQGMJICSA-N Phe-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O MWQXFDIQXIXPMS-UNQGMJICSA-N 0.000 description 2
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 2
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 2
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 2
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 2
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 2
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 2
- SMFQZMGHCODUPQ-ULQDDVLXSA-N Pro-Lys-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SMFQZMGHCODUPQ-ULQDDVLXSA-N 0.000 description 2
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 2
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 2
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 2
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 2
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 2
- QMABBZHZMDXHKU-FKBYEOEOSA-N Pro-Tyr-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QMABBZHZMDXHKU-FKBYEOEOSA-N 0.000 description 2
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 2
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 2
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 2
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 2
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 2
- SMIDBHKWSYUBRZ-ACZMJKKPSA-N Ser-Glu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O SMIDBHKWSYUBRZ-ACZMJKKPSA-N 0.000 description 2
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 2
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 2
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 2
- RQXDSYQXBCRXBT-GUBZILKMSA-N Ser-Met-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RQXDSYQXBCRXBT-GUBZILKMSA-N 0.000 description 2
- KJKQUQXDEKMPDK-FXQIFTODSA-N Ser-Met-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O KJKQUQXDEKMPDK-FXQIFTODSA-N 0.000 description 2
- ASGYVPAVFNDZMA-GUBZILKMSA-N Ser-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)N ASGYVPAVFNDZMA-GUBZILKMSA-N 0.000 description 2
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 2
- QNBVFKZSSRYNFX-CUJWVEQBSA-N Ser-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N)O QNBVFKZSSRYNFX-CUJWVEQBSA-N 0.000 description 2
- ZUXQFMVPAYGPFJ-JXUBOQSCSA-N Thr-Ala-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN ZUXQFMVPAYGPFJ-JXUBOQSCSA-N 0.000 description 2
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 2
- QNJZOAHSYPXTAB-VEVYYDQMSA-N Thr-Asn-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O QNJZOAHSYPXTAB-VEVYYDQMSA-N 0.000 description 2
- NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 2
- CQNFRKAKGDSJFR-NUMRIWBASA-N Thr-Glu-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CQNFRKAKGDSJFR-NUMRIWBASA-N 0.000 description 2
- SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 2
- ZTPXSEUVYNNZRB-CDMKHQONSA-N Thr-Gly-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZTPXSEUVYNNZRB-CDMKHQONSA-N 0.000 description 2
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 2
- XIULAFZYEKSGAJ-IXOXFDKPSA-N Thr-Leu-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XIULAFZYEKSGAJ-IXOXFDKPSA-N 0.000 description 2
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 2
- XIHGJKFSIDTDKV-LYARXQMPSA-N Thr-Phe-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XIHGJKFSIDTDKV-LYARXQMPSA-N 0.000 description 2
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 2
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 2
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 2
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 2
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 2
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 2
- VYVBSMCZNHOZGD-RCWTZXSCSA-N Thr-Val-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VYVBSMCZNHOZGD-RCWTZXSCSA-N 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- WLBZWXXGSOLJBA-HOCLYGCPSA-N Trp-Gly-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 WLBZWXXGSOLJBA-HOCLYGCPSA-N 0.000 description 2
- GWBWCGITOYODER-YTQUADARSA-N Trp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N GWBWCGITOYODER-YTQUADARSA-N 0.000 description 2
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 2
- WTXQBCCKXIKKHB-JYJNAYRXSA-N Tyr-Arg-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WTXQBCCKXIKKHB-JYJNAYRXSA-N 0.000 description 2
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 2
- WURLIFOWSMBUAR-SLFFLAALSA-N Tyr-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O WURLIFOWSMBUAR-SLFFLAALSA-N 0.000 description 2
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 2
- HNWQUBBOBKSFQV-AVGNSLFASA-N Val-Arg-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HNWQUBBOBKSFQV-AVGNSLFASA-N 0.000 description 2
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
- IDKGBVZGNTYYCC-QXEWZRGKSA-N Val-Asn-Pro Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O IDKGBVZGNTYYCC-QXEWZRGKSA-N 0.000 description 2
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 2
- DLYOEFGPYTZVSP-AEJSXWLSSA-N Val-Cys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N DLYOEFGPYTZVSP-AEJSXWLSSA-N 0.000 description 2
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 2
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 2
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 2
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 108010068265 aspartyltyrosine Proteins 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 108010054813 diprotin B Proteins 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 2
- 108010025306 histidylleucine Proteins 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 2
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 108010068488 methionylphenylalanine Proteins 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000002023 papillomaviral effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 108010018625 phenylalanylarginine Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YZFCGHIBLBDZDA-ZLUOBGJFSA-N Cys-Asp-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YZFCGHIBLBDZDA-ZLUOBGJFSA-N 0.000 description 1
- LWTTURISBKEVAC-CIUDSAMLSA-N Cys-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N LWTTURISBKEVAC-CIUDSAMLSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 description 1
- RDIILCRAWOSDOQ-CIUDSAMLSA-N Lys-Cys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RDIILCRAWOSDOQ-CIUDSAMLSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100150705 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tca-9 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- AEEQKUDWJGOFQI-SRVKXCTJSA-N Phe-Cys-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N AEEQKUDWJGOFQI-SRVKXCTJSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710132595 Protein E7 Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BODHJXJNRVRKFA-BZSNNMDCSA-N Tyr-Cys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BODHJXJNRVRKFA-BZSNNMDCSA-N 0.000 description 1
- PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 1
- PDDJTOSAVNRJRH-UNQGMJICSA-N Val-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](C(C)C)N)O PDDJTOSAVNRJRH-UNQGMJICSA-N 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- -1 glycine amino acids Chemical class 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
Definitions
- the present invention relates to vaccine formulations comprising papilloma virus proteins, either as fusion proteins, truncated proteins, or truncated fusion proteins.
- the invention further embraces methods for producing capsomeres of the formulations, as well as prophylactic and therapeutic methods for their use.
- HPV genital papilloma viruses
- HPV 16 18, or 45
- WHO World Health Organization
- precursor lesions of cervical intraepithelial neoplasia are known to be caused by papilloma virus infections
- DNA from the genomes of certain HPV types including for example, strains 16, 18, 33, 35, and 45, have been detected in more than 95 % of tumor biopsies from patients with this disorder, as well as in primary cell lines cultured from the tumors. Approximately 50 to 70% of the biopsied CIN tumor cells have been found to include DNA derived only from HPV 16.
- the protein products of the HPV 16 and HPV 18 early genes E6 and E7 have been detected in cervical carcinoma cell lines as well as in human keratinocytes transformed in vitro [Wettstein, et al. , in PAPILLOMA VIRUSES AND HUMAN CANCER, Pfister (Ed.),CRC Press: Boca Raton, FL 1990 pp 155-179] and a significant percentage of patients with cervical carcinoma have anti-E6 or anti-E7 antibodies.
- the E6 and E7 proteins have been shown to participate in induction of cellular DNA synthesis in human cells, transformation of human keratinocytes and other cell types, and tumor formation in transgenic mice [Arbeit, et al. , J. Virol.
- the clinical manifestation of primary infection by rabbit and bovine papilloma virus can be prevented by vaccination with wart extracts or viral structural proteins [Altmann, et al. , supra; Campo, Curr. Top. In Microbiol and Immunol. 186:255-266 (1994); Yindle and Frazer, Curr. Top. In Microbiol. and Immunol. 186;2ll-253 (1994)].
- Rodents previously vaccinated with vaccinia recombinants encoding HPV 16 early proteins E6 or E7, or with synthetic E6 or E7 peptides are similarly protected from tumor formation after inoculation of HPV 16 transformed autologous cells [Altman, et al.
- the present invention provides therapeutic and prophylactic vaccine formulations comprising chimeric human papilloma capsomeres.
- the invention also provides therapeutic methods for treating patients infected with an HPV as well as prophylactic methods for preventing HPV infection in a susceptible individual. Methods for production and purification of capsomeres and proteins of the invention are also contemplated.
- prophylactic vaccinations for prevention of HPV infection are considered which incorporate the structural proteins LI and L2 of the papilloma vims.
- Development of a vaccine of this type faces significant obstacles because papilloma viruses cannot be propagated to adequate titers in cell cultures or other experimental systems to provide the viral proteins in sufficient quantity for economical vaccine production.
- recombinant methodologies to express the proteins are not always straightforward and often results in low protein yield.
- vims-like particles similar in make up to viral capsid structures, have been described which are fo ⁇ ned in Sf-9 insect cells upon expression of the viral proteins LI and L2 (or LI on its own) using recombinant vaccinia or baculovinis.
- VLPs Purification of the VLPs can be achieved very simply by means of centrifugation in CsCl or sucrose gradients [Kimbauer. ei al. . Proc Natl. Acad. Sci. (USA), 99: 12180-12814 (1992): Kimbaurer, et al. , J. Virol. 67:6929-6936 (1994); Proso, et al , J. Virol. 6774: 1936-1944 ( 1992): Sasagawa. et al , Virology 2076: 126-195 (1995): Volpers, et al , J. Virol. 69:3258-3264 (1995); Zhou, et al , J. Gen. Virol.
- WO 93/02184 describes a method in which papilloma vims-like particles (VLPs) are used for diagnostic applications or as a vaccine against infections caused by the papilloma vims.
- VLPs papilloma vims-like particles
- WO 94/00152 describes recombinant production of LI protein which mimics the conformational neutralizing epitope on human and animal papilloma virions.
- therapeutic vaccinations are provided to relieve complications of, for example, cervical carcinoma or precursor lesions resulting from papilloma virus infection, and thus represent an alternative to prophylactic intervention.
- Vaccinations of this type may comprise early papilloma vims proteins, principally E6 or E7. which are expressed in the persistently infected cells. It is assumed that, following administration of a vaccination of this type, cytotoxic T-cells might be activated against persistently infected cells in genital lesions.
- the target population for therapeutic intervention is patients with HPV- associated pre-malignant or malignant genital lesions.
- PCT patent application WO 93/20844 discloses that the early protein E7 and antigenic fragments thereof of the papilloma vims from HPV or BPV is therapeutically effective in the regression, but not in the prevention, of papilloma vims tumors in mammals. While early HPV proteins have been produced by recombinant expression in E. coli or suitable eukaryotic cell types, purification of the recombinant proteins has proven difficult due to inherent low solubility and complex purification procedures which generally require a combination of steps, including ion exchange chromatography, gel filtration and affinity chromatography.
- vaccine formulations comprising papilloma vims capsomeres which comprise either: (i) a first protein that is an intact viral protein expressed as a fusion protein comprised in part of amino acid residues from a second protein; (ii) a tmncated viral protein; (iii) a tmncated viral protein expressed as a fusion protein comprised in part of amino acid residues from a second protein, or (iv) some combination of the three types of proteins.
- vaccine formulations are provided comprising capsomeres of bovine papilloma vims (BPV) and human papilloma vims.
- Preferred bovine vims capsomeres comprise protein from bovine papilloma vims type I.
- Preferred human virus capsomeres comprise proteins from any one of human papilloma vims strains HPV6, HPV11 , HPV16, HPV18, HPV33, HPV35, and HPV45.
- the most preferred vaccine formulations comprise capsomeres comprising proteins from HPV 16.
- capsomere vaccine formulations of the invention comprise a first intact viral protein expressed as a fusion protein with additional amino acid residues from a second protein.
- Preferred intact viral proteins are the structural papilloma viral proteins LI and L2.
- Capsomeres comprised of intact viral protein fusions may be produced using the LI and L2 proteins together or the LI protein alone.
- Preferred capsomeres are made up entirely of LI fusion proteins, the amino acid sequence of which is set out in SEQ ID NO: 2 and encoded by the polynucleotide sequence of SEQ ID NO: 1 .
- Amino acids of the second protein can be derived from numerous sources (including amino acid residues from the first protein) as long as the addition of the second protein amino acid residues to the first protein pe ⁇ nits formation of capsomeres.
- addition of the second protein amino acid residues inhibits the ability of the intact viral protein to form vims-like particle stmctures; most preferably, the second protein amino acid residues promote capsomere formation.
- the second protein may be any human tumor antigen, viral antigen, or bacterial antigen which is important in stimulating an immune response in neoplastic or infectious disease states.
- the second protein is also a papilloma vims protein.
- the second protein be the expression product of papilloma vims early gene. It is also preferred, however, that the second protein be selected from group of El , E2, E3, E4, E5. E6, and E7 — early gene products encoded in the genome of papilloma vims strains HVP6, HPV1 1 , HPV18, HPV33, HPV35, or HPV 45. It is most preferred that the second protein be encoded by the HPV16 E7 gene, the open reading frame of which is set out in SEQ ID NO: 3. Capsomeres assembled from fusion protein subunits are referred to herein as chimeric capsomeres.
- the vaccine formulation of the invention is comprised of chimeric capsomeres wherein LI protein amino acid residues make up approximately 50 to 99 % of the total fusion protein amino acid residues. In another embodiment, LI amino acid residues make up approximately 60 to 90% of the total fusion protein amino acid residues; in a particularly preferred embodiment. LI amino acids comprise approximately 80 % of the fusion protein amino acid residues.
- capsomere vaccine formulations are provided that are comprised of tmncated viral proteins having a deletion of one or more amino acid residues necessary for formation of a vims-like particle. It is preferred that the amino acid deletion not inhibit fomiation of capsomeres by the tmncated protein, and it is most preferred that the deletion favor capsomere formation.
- Preferred vaccine formulations of this type include capsomeres comprised of tmncated LI with or without L2 viral proteins. Particularly preferred capsomeres are comprised of tmncated LI proteins.
- Tmncated proteins contemplated by the invention include those having one or more amino acid residues deleted from the carboxy terminus of the protein, or one or more amino acid residues deleted from the amino terminus of the protein, or one or more amino acid residues deleted from an internal region ⁇ i.e. , not from either terminus) of the protein.
- Preferred capsomere vaccine formulations are comprised of proteins tmncated at the carboxy terminus. In formulations including LI protein derived from HPV16, it is preferred that from 1 to 34 carboxy terminal amino acid residues are deleted. Relatively shorter deletions are also contemplated which offer the advantage of minor modification of the antigenic properties of the LI proteins and the capsomeres formed thereof.
- 34 amino acid residues be deleted from the LI sequence, corresponding to amino acids 472 to 505 in HPV 16 set out in SEQ ID NO: 2, and encoded by the polynucleotide sequence corresponding to nucleotides 1414 to 1516 in the human HPV16 LI coding sequence set out in SEQ ID NO: 1.
- the deleted amino acid sequence comprise the nuclear localization region of the protein. In the LI protein of HPV 16. the nuclear localization signal is found from about amino acid residue 499 to about amino acid residue 505. Following expression of LI proteins wherein the NLS has been deleted, assembly of capsomere stmctures occurs in the cytoplasm of the host cell.
- capsomeres which result from assembly of tmncated proteins wherein additional amino acid sequences do not replace the deleted protein sequences are necessarily not chimeric in nature.
- capsomere vaccine fo ⁇ nulations comprising tmncated viral protein expressed as a fusion protein adjacent amino acid residues from a second protein.
- Preferred tmncated viral proteins of the invention are the structural papilloma viral proteins LI and L2.
- Capsomeres comprised of tmncated viral p otein fusions may be produced using LI and L2 protein components together or LI protein alone.
- Preferred capsomeres are those comprised of LI protein amino acid residues.
- Tmncated viral protein components of the fusion proteins include those having one or more amino acid residues deleted from the carboxy terminus of the protein, or one or more amino acid residues deleted from the amino terminus of the protein, or one or more amino acid residues deleted from an internal region (i.e. , not from either terminus) of the protein.
- Preferred capsomere vaccine formulations are comprised of proteins tmncated at the carboxy terminus. In those formulations including LI protein derived from HPV16, it is preferred that from 1 to 34 carboxy terminal amino acid residues are deleted. Relatively shorter deletions are also contemplated that offer the advantage of minor modification of the antigenic properties of the LI protein component of the fusion protein and the capsomeres formed thereof.
- 34 amino acid residues be deleted from the LI sequence, corresponding to amino acids 472 to 505 in HPV16 set out in SEQ ID NO: 2. and encoded by the polynucleotide sequence corresponding to nucleotides 1414 to 1516 in the human HPV 16 LI coding sequence set out in SEQ ID NO: 1.
- the deleted amino acid sequence comprise the nuclear localization region, or sequence, of the protein.
- Amino acids of the second protein can be derived from numerous sources as long as the addition of the second protein amino acid residues to the first protein permits formation of capsomeres. Preferably, addition of the second protein amino acid residues promotes or favors capsomere formation. Amino acid residues of the second protein can be derived from numerous sources, including amino acid residues from the first protein.
- the second protein is also a papilloma vims protein. It also preferred that the second protein be the expression product of papilloma vims early gene. It is most preferred, however, that the second protein be selected from group of early gene products encoding by papilloma vims El . E2, E3. E4, E5, E6, and E7 genes.
- the vaccine fo ⁇ nulation of the invention is comprised of chimeric capsomeres wherein LI protein amino acid residues make up approximately 50 to 99 % of the total fusion protein amino acid residues. In another embodiment, LI amino acid residues make up approximately 60 to 90% of the total fusion protein amino acid residues; in a particularly preferred embodiment, LI amino acids comprise approximately 80% of the fusion protein amino acid residues.
- proteins of the vaccine formulations are produced by recombinant methodologies, but in formulations comprising intact viral protein, the proteins may be isolated from natural sources. Intact proteins isolated from natural sources may be modified in vitro to include additional amino acid residues to provide a fusion protein of the invention using covalent modification techniques well known and routinely practiced in the art. Similarly, in formulations comprising tmncated viral proteins, the proteins may be isolated from natural sources as intact proteins and hydrolyzed in vitro using chemical hydrolysis or enzymatic digestion with any of a number of site-specific or general proteases, the tmncated protein subsequently modified to include additional amino acid resides as described above to provide a tmncated fusion protein of the invention.
- recombinant molecular biology techniques can be utilized to produce DNA encoding either the desired intact protein, the tmncated protein, or the tmncated fusion protein.
- Recombinant methodologies required to produce a DNA encoding a desired protein are well known and routinely practiced in the art.
- Laboratory manuals for example Sambrook. et al . (eds.), MOLECULAR CLONING: A LABORATORY MANL AL. Cold Spring Harbor Press: Cold Spring Harbor, NY (1989) and Ausebel et al . (eds.). PROTOCOLS IN MOLECULAR BIOLOGY. John Wiley & Sons. Inc.
- protein expression can be carried out using either viral or eukaryotic vectors.
- Preferable vectors include any of the well known prokaryotic expression vectors, recombinant baculovimses, COS cell specific vectors, vaccinia recombinants, or yeast- specific expression constmcts.
- the proteins may first be isolated from the host cell of its expression and thereafter incubated under conditions which permit self-assembly to provide capsomeres. Alternatively, the proteins may be expressed under conditions wherein capsomeres are formed in the host cell.
- LI proteins are expressed from DNA encoding six additional histidines at the carboxy terminus of the LI protein coding sequence.
- LI proteins expressed with additional histidines are most preferably expressed in E. coli and the His LI proteins can be purified using nickel affinity chromatography. His LI proteins in cell lysate are suspended in a denaturation buffer, for example. 6 M guanidine hydrochloride or a buffer of equivalent denaturing capacity, and then subjected to nickel chromatography. Protein eluted from the nickel chromatography step is renatured, for example in 150 inM NaCl.
- Triton-X 100 10 mM HEPES (N-2-hydroxyethyl piperazine-N'-2 ethane sulfonic acid), pH 7.4.
- assembly of capsomeres takes place after dialysis of the purified proteins, preferably after dialysis against 150 M NaCl. 25 mM Ca 2 + , 10% DMSO (dimethyl sulfoxide).
- Triton-X 100 10 mM Tris [tris-(hydroxymethyl) amino- methane] acetic acid with a pH value of 5.0.
- capsomeres can be monitored by electron microscopy, and, in instances wherein capsomeres are comprised of fusion proteins, the presence of various protein components in the assembled capsomere can be confirmed by Western blot analysis using specific antisera.
- methods are provided for therapeutic treatment of individuals infected with HPV comprising the step of administering to a patient in need thereof an amount of a vaccine formulation of the invention effective to reduce the level of HPV infection.
- the invention also provide methods for prophylactic treatment of individuals susceptible to HPV infection comprising the step of administering to an individual susceptible to HPV infection an amount of a vaccine formulation of the invention effective to prevent HPV infection.
- infected individuals can be easily identified using standard diagnostic techniques, susceptible individuals may be identified, for example, as those engaged in sexual relations with an infected individual. However, due to the high frequency of HPV infection, all sexually active persons are susceptible to papilloma vims infection.
- Administration of a vaccine formulation can include one or more additional components such as pharmaceutically acceptable carriers, diluents, adjuvants, and/or buffers.
- Vaccines may be administered at a single time or at multiple times.
- Vaccine formulation of the invention may be delivered by various routes including, for example, oral, intravenous, intramuscular, nasal, rectal, transdermal. vaginal, subcutaneous, and intraperitoneal administration.
- Vaccine formulations of the invention offer numerous advantages when compared to conventional vaccine preparations.
- capsomeres can promote elimination of persistently infected cells in. for example, patients with CIN or cervical carcinoma. Additionally, therapeutic vaccinations of this type can also serve a prophylactic purpose in protecting patients with CIN lesions from re-infection.
- capsomeres can escape neutralization by pre-existing anticapsid antibodies and thereby posses longer circulating half-life as compared to chimeric vims-like particles.
- Vaccine formulations comprising chimeric capsomeres can provide the additional advantage of increased antigenicity of both protein components of the fusion protein from which the capsomere is formed.
- protein components of the underlying capsomere may be buried in the overall stmcture as a result of internalized positioning within the VLP itself.
- epitopes of the protein components may be sterically obstmcted as a result of capsomere-to-capsomere contact, and therefore unaccessible for eliciting an immune response.
- Preliminary results using L1/E7 fusion proteins to produce VLPs support this position in that no antibody response was detected against the E7 component.
- Example 1 describes constmction of expression vectors to produce fusion, or chimeric. viral proteins.
- Example 2 relates to generation of recombinant baculovimses for expression of viral proteins.
- Example 3 addresses purification of capsomeres.
- Example 4 describes an immunization protocol for production of antisera and monoclonal antibodies.
- Example 5 provides a peptide ELISA to quantitate capsomere formation.
- Example 6 describes an antigen capture ELISA to quantitate capsomere formation.
- Example 7 provides a hemagglutinin assay to assay for the induction of neutralizing antibodies.
- DNA encoding the HPV 16 LI open reading frame was excised from plasmid 16-114/k-Ll/L2-pSynxtVT [Kirnbauer et al., J. Virol. 67:6929-6936 (1994)] using BglE and the resulting fragment subcloned into pUC19 (New England Biolabs, Beverly, MA) previously linearized at the unique Bam ⁇ I restriction site. Two basic expression constmcts were first generated to permit subsequent insertion of DNA to allow fusion protein expression.
- the second construct, HPV 16 LI ⁇ C . encoded a protein having a 34 amino acid deletion of the carboxy te ⁇ ninal LI residues.
- Other constmcts include an EcoRV restriction site at the position of the deletion for facilitated insertion of DNA encoding other protein sequences. Addition of the EcoRV site encodes two non-Ll protein amino acids, aspartate and isoleucine.
- Two primers (S ⁇ Q ID NOs: 5 and 6) were designed to amplify the pUC19 vector and the complete HPV 16 LI coding sequence, except nucleotides 916 through 942 in S ⁇ Q ID NO: 1. Primers were synthesized to also introduce a unique EcoRV restriction site (underlined in S ⁇ Q ID NOs: 5 and 6) at the termini of the amplification product.
- the resulting PCR product was digested with EcoRV to provide complementary ends and the digestion product circularized by ligation.
- Ligated DNA was transformed into E. coli using standard techniques and plasmids from resulting colonies were screened for the presence of an EcoRV restriction site.
- One clone designated HPV 16 LI ⁇ 310 was identified as having the appropriate twenty-seven nucleotide deletion and this constmct was used to insert DNA fragments encoding other HPV 16 proteins at the EcoRV site as discussed below.
- Two primers (S ⁇ Q ID NOs: 7 and 8) were designed complementary to the HPV 16 LI open reading frame such that the primers abutted each other to permit amplification in reverse directions on the template DNA comprising HPV 16 LI -encoding sequences in pUC19 described above.
- Each primer introduced an EcoRV restriction site at the terminus of the amplification product.
- the EcoRV site was followed by a TAA translational stop codon positioned ,uch that the amplification product, upon hgation of the EcoRV ends to circularize, would include deletion of the 34 carboxy terminal LI amino acids.
- PCR was performed to amplify the partial LI open reading frame and the complete vector.
- the amplification product was cleaved with EcoRV. circularized with T4 DNA ligase, and transformed into E. coli DH5 ex cells. Plasmids from viable clones were analyzed for the presence of an EcoRV site which would linearize the plasmid.
- One positive constmct designated PUCHPV16L1 ⁇ C was identified and used to insert DNA from other HPV 16 proteins utilizing the EcoRV site.
- DNA fragments of HPV 16 ⁇ 7 encoding amino acids 1-50, 1 -60. 1-98. 25-75. 40-98, 50-98 in SEQ ID NO: 4 were amplified using primers that introduced terminal 5' EcoRV restriction sites in order to facilitate insertion of the fragment into either HPV 16 LI ⁇ 310 and HPV 1 6L1 ⁇ C modified sequence. In the various amplification reactions, primer ⁇ 7.
- SEQ ID NO: 9 was used in combination with primer E7.2 (SEQ ID NO: 10) to generate a DNA fragment encoding E7 amino acids 1- 50: with primer E7.3 (SEQ ID NO: 1 1) generate a DNA fragment encoding E7 amino acids 1 -60: or with primer E7.4 (SEQ ID NO: 12) generate a DNA fragment encoding E7 amino acids 1-98.
- primer pairs E7.5 (SEQ ID NO: 13) and E7.6 (SEQ ID NO: 14) were used to amplify a DNA fragment encoding E7 amino acids 25-75: E7.7 (SEQ ID NO: 15) and E7.4 (SEQ ID NO: 12) were used to amplify a DNA fragment encoding E7 amino acids 40-98; and E7.8 (SEQ ID NO: 16) and E7.4 (SEQ ID NO: 12) were used to amplify a DNA fragment encoding E7 amino acids 50-98.
- nucleotides from DNA encoding the influenza matrix protein (SEQ ID NO: 17) was amplified using the primer pair set out in SEQ ID NOs: 19 and 20. Both primers introduced an EcoRV restriction site in the amplification product.
- PCR products from each amplification reaction were cleaved with EcoRV and inserted into the EcoRV site of either the HPV 16 LI ⁇ 310 and HPV16L1 ⁇ C sequences previously linearized with the same enzyme.
- Clal digestion was employed, taking advantage of a restriction site overlapping the newly created EcoRV restriction site CGATATCGAT) and included in the upstream primer.
- insert orientation was determined utilizing a NsH restriction site within the E7 coding region.
- HPV 16 LI ⁇ C sequence includes DNA from the EcoRV site that results in translation of amino acids not normally found in wild-type LI polypeptides. Thus, a series of expression constmctions was designed in which the artificial Ec ⁇ Rv site was eliminated. The LI sequence for this series of expression constmcts was designated HPV
- fragment 1 was generated using primers PI (S ⁇ Q ID NO: 21) and P2 (S ⁇ Q ID NO: 22) and fragment 2 using primers P3 (S ⁇ Q ID NO: 23) and P4 (S ⁇ Q ID NO: 24).
- Primer P2 S ⁇ Q ID NO: 22 CCATGCATTCCTGCTTGTAGTAAAAATTTGCGTCC
- Primer P4 SEQ ID NO: 24 CATCTGAAGCTTAGTAATGGGCTCTGTCCGGTTCTG
- the two purified products were used as templates in another PCR reaction using p ⁇ mers PI and P4 only
- the resulting amplification product was digested with enzymes EcoNI and H dIII inserted into the ⁇ PV 16L1 ⁇ C expression constmct desc ⁇ bed above following digestion with the same enzymes.
- the resulting expression constmct differed from the original ⁇ PV16L1 ⁇ C constmct with DNA encoding LI and ⁇ 7 amino acids 1-50 by loss of the two internal EcoRV restriction sites
- the first EcoRV site was replaced by DNA encoding nativ e LI alanine and glycine amino acids in this position and the second was replaced by a translational stop signal.
- the expression constmct. designated ⁇ PV 16 LI ⁇ C ⁇ 7 1-52 contained the first 52 amino acids of ⁇ PV 16 ⁇ 7 as a result of using primer P4 which also encodes E7 amino acids residues histidine at position 51 and tyrosine at position 52 ⁇ PV 16 LI ⁇ C* E7 1-52 was then used to generate additional ⁇ PV 16 LI ⁇ C expression constmcts further including DNA encoding E7 amino acids 1 55 using p ⁇ mer PI (SEQ ID NO: 21) in combination with primer P5 (SEQ ID NO 25), E7 amino acids 1-60 with primer pair PI and P6 (SEQ ID NO' 26), and E7 amino acids 1-65 with primer pair PI and P7 (SEQ ID NO. 27)
- the additional animo acid- encoding DNA sequences in the amplification products arose from design of the primers to include additional nucleotides for the desired amino acids.
- HPV 16 LI ⁇ C E7 1 -70 was generated using template DNA encoding HPV 16 LI ⁇ C* E7 1 -66 and the primer pair PI and P8 (SEQ ID NO: 28).
- Spodoptera frugiperda (Sf9) cells were grown in suspension or monolayer cultures at 27° in TNMF ⁇ medium (Sigma) supplemented with
- ⁇ PV 16 LI -based recombinant baculovims constmction Sf9 cells were transfected with 10 ⁇ g of transfer plasmid together with 2 ⁇ g of linearized Baculo-Gold DNA (PharMingen, San Diego, CA). Recombinant viruses were purified by according to manufacturer's suggested protocol.
- the two supernatants were combined, layered onto a two-step gradient containing 14 ml of 40% sucrose on top of 8 ml of CsCl solution (4.6 g CsCl per 8 ml in extraction buffer), and centrifuged in a Sorval AH629 swinging bucket rotor for 2 hours at 27,000 rpm at 10°C.
- the interface region between the CsCl and the sucrose along with the CsCl complete layer were collected into 13.4 ml Quickseal tubes (Beckman) and extraction buffer added to adjust the volume 13.4 ml. Samples were centrifuged overnight at 50.000 rpm at 20°C in a Beckman 70 TI rotor.
- Vims-like particles and capsomeres were separated from the fractions identified above by sedimentation on 10 to 50% sucrose gradients. Peak fractions from CsCl gradients were pooled and dialyzed for 2 hours against 5 mM HEPES (pH 7.5). Half of the dialysate was used to produce capsomeres by disassembly of intact VLPs overnight by adding EDTA (final concentration 50 mM), EGTA (50 mM), DTT (30 mM). NaCl (100 mM), and Tris/HCl, pH 8.0, (10 mM). As control, NaCl and Tris/HCl only were added to the other half.
- EDTA For analysis of capsomeres produced from disassembled VLPs, EDTA. EGTA, and DTT (final concentration 5 mM each) were added to the sucrose cushions which were centrifuged at 250,000 x g for 2 to 4 hours at 4°C. Fractions were collected by puncturing tubes from the bottom. A 1 : 10 dilution of each fraction was then analyzed by antigen capture ELISA.
- mice are immunized subcutaneously three times, every four weeks with approximately 60 ⁇ g of HPV chimeric capsomeres mixed 1 : 1 with complete or incomplete Freund's Adjuvants in a total volume of 100 ⁇ l.
- mice are sacrificed and blood is collected by cardiac puncture.
- Microtiter plates (Dynatech) are coated overnight with 50 ⁇ l of peptide E701 [Muller et al , 1982] at a concentration of 10 ⁇ g/ml in PBS. Wells are blocked for 2 hour at 37°C with 100 ⁇ l of buffer containing 5 % BSA and 0.05 % Tween 20 in PBS and washed three times with PBS containing 0.05 % Tween 20. After the third wash. 50 ⁇ l of sera diluted 1 :5000 in BSA/Tween 20/PBS is added to each well and incubation carried out for 1 hour.
- an antigen capture ELISA was utilized. Microtiter plates were coated overnight with 50 ⁇ l/well of a 1:500 dilution (final concentration of 2 ⁇ g per ml, in PBS) with a protein A purified mouse monoclonal antibody immunospecific for HPV 16 Ll (antibodies 25/C, MM07 and Ritti 1 were obtained from mice immunized with HPV 16 VLPs).
- Plates were blocked with 5 % milk/PBS for 1 hour and 50 ⁇ l of fractions of CsCl gradients were added for 1 hour at 37°C using a 1 :300 dilution (in 5 % milk/PBS). After three washings with PBS/0.05 % Tween 20. 50 ⁇ l of a polyclonal rabbit antiserum (1:3000 dilution in milk PBS), raised against HPV 16 VLPs was added and plates were incubated at 37° for 1 hour. Plates were washed again and further incubated with 50 ⁇ l of a goat-anti-rabbit peroxidase conjugate (Sigma) diluted 1 :5000 in PBS containing 5 % milk for 1 hour. After final washing, plates were stained with
- ABTS substrate for 30 minutes and extinction measured at 490 nm in a Dynatech automated plate reader.
- the assay also included wells coated only with PBS.
- VLPs with EDTA/DTT to disassemble particles.
- Treated particle preparations were assayed in the antigen-capture ELISA and readings compared to untreated controls.
- 40 ⁇ l of VLPs was incubated overnight at 4°C in 500 ⁇ l of dismption buffer containing 30 mM DTT. 50 mM EGTA, 60 mM EDTA, 100 mM NaCl, and 100 mM Tris/HCl. pH 8.0. Aliquots of treated and untreated particles were used in the above capture ELISA in a 1 :20-1 :40 dilution.
- a hemagglutination inhibition assay is carried out as briefly described below. This assay is based on previous observations that vims-like particles are capable of hemagglutinizing red blood cells.
- mice are immunized with any of a chimeric capsomere vaccine and sera is collected as described above in Example 4.
- HPV16 Ll vims like particles (VLPs) and bovine PVl (BPV) Ll VLPs are assayed in parallel with a chimeric capsomere preparation.
- VLPs HPV16 Ll vims like particles
- BPV bovine PVl
- the HPV 16 or BPV1 VLPs are first incubated with or without sera collected from immunized mice after which red blood cells are added. The extent to which preincubation with mouse cera inhibits red blood cell hemagglutinization is an indication of the neutralizing capacity of the mouse sera. The experiments are then repeated using chimeric capsomeres in order to determine the neutralizing effect of the mouse sera on the vaccine. A brief protocol for the hemagglutination inhibition assay is described below.
- heparin 1000 usp units/ml
- Red blood cells are washed three times with PBS followed by centrifugation and resuspension in a volume of 10 ml.
- erythrocytes are resuspended in 0.5 ml PBS and stored at 4°C for up to three days.
- hemagglutinin assay 70 ⁇ l of the suspension is used per well on a 96-well plate.
- Chimeric capsomere aliquots from CsCl gradients are dialyzed for one hour against 10 mM Hepes (pH 7.5) and 100 ⁇ l of two-fold serial dilutions in PBS are added to mouse erythrocytes in round-bottom 96-well microtiter plates which are further incubated for 3- 16 hours at 4°C.
- capsomeres are incubated with dilutions of antibodies in PBS for 60 minutes at room temperature and then added to the erythrocytes. The level of erythrocyte hemagglutination, and therefore the presence of neutralizing antibodies, is determined by standard methods.
- mouse sera generated against chimeric capsomeres comprising HPV16L1 ⁇ C protein in association with E7 amino acid residues 1-98 was observed to inhibit hemagglutination by HPV16 VLPs, but not by BPV VLPs.
- the mouse sera was therefore positive for neutralizing antibodies against the human VLPs and this differential neutralization was most likely the result of antibody specificity for epitopes against which the antibodies were raised.
- MOLECULE TYPE DNA (genomic)
- ACT ACA TAT AAA AAT ACT AAC TTT AAG GAG TAC CTA CGA CAT GGG GAG 110 Thr Thr Tyr Lys Asn Thr Asn Phe Lys Glu Tyr Leu Arg His Gly Glu 355 360 365
- Tyr Phe Pro lie Lys Lys Pro Asn Asn Asn Lys lie Leu Val Pro Lys 50 55 60
- Glu Cys lie Ser Met Asp Tyr Lys Gin Thr Gin Leu Cys Leu lie Gly 145 150 155 160
- Cys Lys Pro Pro lie Gly Glu His Trp Gly Lys Gly Ser Pro Cys Thr 165 170 175
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ503830A NZ503830A (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
JP2000515014A JP4520034B2 (en) | 1997-10-06 | 1998-10-06 | Papillomavirus capsomere vaccine formulation and method of use |
DK98950930T DK1021547T3 (en) | 1997-10-06 | 1998-10-06 | Vaccine formulations containing papilloma virus capsomes and methods for their use |
KR1020007003721A KR20010030969A (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
PL98339735A PL195332B1 (en) | 1997-10-06 | 1998-10-06 | Pappiloma virus capsomer vaccine compositions and methods of applying them |
IL13552898A IL135528A0 (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
CA002305382A CA2305382A1 (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
DE69836753T DE69836753T2 (en) | 1997-10-06 | 1998-10-06 | PAPILLOMA VIRUS CAPSOMERE VACCINE FORMULATIONS AND THEIR USES |
AU96846/98A AU9684698A (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
HU0004360A HU225893B1 (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
EP98950930A EP1021547B1 (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
BR9814606-8A BR9814606A (en) | 1997-10-06 | 1998-10-06 | Vaccine formulation and methods of treating an individual infected with an hpv virus and preventing papillomavirus infection |
IL135528A IL135528A (en) | 1997-10-06 | 2000-04-06 | Papilloma virus capsomere vaccine formulations and methods of use |
NO20001768A NO328128B1 (en) | 1997-10-06 | 2000-04-06 | Antigenic formulation comprising a human papillomavirus capsomer for use as a vaccine, as well as its use for the preparation of a pharmaceutical composition for the treatment and prevention of HPV infection and conditions related thereto. |
CY20071100114T CY1105963T1 (en) | 1997-10-06 | 2007-01-29 | CAPSOMEPIDIAN VACCINE COMPOSITIONS AND METHODS OF USE |
IL190554A IL190554A0 (en) | 1997-10-06 | 2008-04-01 | Papilloma virus capsomere vaccine formulations and methods of use |
NO20091761A NO20091761L (en) | 1997-10-06 | 2009-05-04 | Virus vaccine vaccine, method of preparation and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/944,368 US6228368B1 (en) | 1997-10-06 | 1997-10-06 | Papilloma virus capsomere formulations and method of use |
US08/944,368 | 1997-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999018220A1 true WO1999018220A1 (en) | 1999-04-15 |
Family
ID=25481268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/020965 WO1999018220A1 (en) | 1997-10-06 | 1998-10-06 | Papilloma virus capsomere vaccine formulations and methods of use |
Country Status (21)
Country | Link |
---|---|
US (4) | US6228368B1 (en) |
EP (2) | EP1690941B1 (en) |
JP (3) | JP4520034B2 (en) |
KR (1) | KR20010030969A (en) |
AT (2) | ATE349536T1 (en) |
AU (1) | AU9684698A (en) |
BR (1) | BR9814606A (en) |
CA (1) | CA2305382A1 (en) |
CY (1) | CY1105963T1 (en) |
CZ (1) | CZ302351B6 (en) |
DE (2) | DE69841342D1 (en) |
DK (1) | DK1021547T3 (en) |
ES (2) | ES2280104T3 (en) |
HU (1) | HU225893B1 (en) |
IL (3) | IL135528A0 (en) |
NO (2) | NO328128B1 (en) |
NZ (1) | NZ503830A (en) |
PL (1) | PL195332B1 (en) |
PT (1) | PT1021547E (en) |
TR (1) | TR200001842T2 (en) |
WO (1) | WO1999018220A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050424A2 (en) * | 1998-03-27 | 1999-10-07 | Margaret Anne Stanley | Fusion protein comprising a sequence from a major coat protein of a papovavirus |
WO2000035478A1 (en) * | 1998-12-11 | 2000-06-22 | The University Of Queensland | Treatment of papillomavirus infections |
WO2000047722A2 (en) * | 1999-02-11 | 2000-08-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Chimeric virus-like particles or chimeric capsomers from bvp (bovine papilloma virus) |
WO2000073464A1 (en) * | 1999-06-01 | 2000-12-07 | Medigene Aktiengesellschaft | Cytotoxic t-cell epitopes of the papillomavirus l1-protein and use thereof in diagnostics and therapy |
WO2000073335A1 (en) * | 1999-06-01 | 2000-12-07 | Medigene Aktiengesellschaft | Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy |
WO2000073790A1 (en) * | 1999-06-01 | 2000-12-07 | Medigene Aktiengesellschaft | Test system for in-vitro detection of an antigen-specific immune response |
WO2002038769A2 (en) * | 2000-11-09 | 2002-05-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
WO2002043757A2 (en) * | 2000-12-01 | 2002-06-06 | Medigene Aktiengesellschaft | Medicament for preventing or treating tumors caused by human papilloma virus type 18 |
EP1250593A1 (en) * | 1999-12-09 | 2002-10-23 | Medimmune, Inc. | IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs) |
WO2003018623A2 (en) * | 2001-08-31 | 2003-03-06 | University Of Cape Town | Papillomavirus proteins and pharmaceutical compositions |
JP2003511010A (en) * | 1999-08-25 | 2003-03-25 | メルク エンド カムパニー インコーポレーテッド | Synthetic human papillomavirus gene optimized for expression in human cells |
US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
US7183377B2 (en) | 1997-05-29 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Human FRP and fragments thereof including methods for using them |
US7641896B2 (en) | 2002-07-05 | 2010-01-05 | Folia Biotech Inc. | Adjuvant viral particle |
US7947651B2 (en) | 2000-04-10 | 2011-05-24 | The United States Of America As Represented By The Department Of Health And Human Services | Secreted frizzled related protein, sFRP, fragments and methods of use thereof |
US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
WO2016026919A1 (en) * | 2014-08-20 | 2016-02-25 | Ruprecht-Karls-Universität Heidelberg | Vaccines and manufacturing methods for treatment and prevention of disease |
WO2021013067A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 6 l1 protein |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT809700E (en) * | 1994-10-07 | 2006-09-29 | Univ Loyola Chicago | PARTICLES SIMILAR TO PAPILLOMAVIRUS AND FUSEOUS PROTEINS, AND METHODS FOR THEIR PRODUCTION |
US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
US20020039584A1 (en) * | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
US7494658B2 (en) * | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
US7182947B2 (en) * | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
CA2229955C (en) * | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
FI107932B (en) * | 1999-02-16 | 2001-10-31 | Mikael Paronen | Polymer membranes and process for their preparation |
WO2000054730A2 (en) * | 1999-03-18 | 2000-09-21 | The President & Fellows Of Harvard College | Compositions preparations and uses of human papillomavirus l1 protein |
EP1425423B1 (en) | 2001-08-13 | 2010-06-23 | University of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
WO2003068933A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
AU2003232951B2 (en) † | 2002-05-17 | 2009-07-23 | University Of Cape Town | Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. |
SE0202896D0 (en) * | 2002-10-01 | 2002-10-01 | Quantovir Ab | Method for estimating the risk of carcinoma development |
SE0202897D0 (en) * | 2002-10-01 | 2002-10-01 | Quantovir Ab | Method and kit for quantitative and qualitative determination of human papillomavirus |
WO2004062584A2 (en) * | 2003-01-10 | 2004-07-29 | Regents Of The University Of Colorado | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection |
US7172773B2 (en) * | 2004-04-26 | 2007-02-06 | Renew Life Inc. | Food supplement formulation |
CN101010099B (en) * | 2004-09-10 | 2011-11-09 | 旭硝子株式会社 | Edible vaccine |
JP5020825B2 (en) | 2004-12-08 | 2012-09-05 | ジェン−プローブ・インコーポレーテッド | Detection of nucleic acids from multiple forms of human papillomavirus |
US7314630B2 (en) * | 2005-01-07 | 2008-01-01 | Yao-Xiong Hu | Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified |
US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
US9428555B2 (en) * | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
BRPI0810951B8 (en) * | 2007-05-29 | 2021-05-25 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | hpv6 l1 protein, polynucleotide, vector, cell, virus-like particle (vlp) hpv6, method for producing truncated hpv6 l1 protein, vaccine for prevention of condyloma acuminatum or hpv infections, use of truncated hpv6 l1 protein, method for prevention of condyloma acuminata or hpv infections, method of obtaining a vlp of a hpv6 l1 protein, and method of producing a vaccine for the prevention of condyloma acuminatum or hpv infections |
US8507811B2 (en) * | 2009-02-02 | 2013-08-13 | Apple Inc. | Touch sensor panels with reduced static capacitance |
EP2377879A1 (en) * | 2010-04-14 | 2011-10-19 | Deutsches Krebsforschungszentrum | N-terminal HPV E7 fusion proteins |
CN106795518A (en) * | 2014-06-19 | 2017-05-31 | 科罗拉多大学董事会,法人 | Human papilloma virus's construct |
US11382700B2 (en) | 2020-05-08 | 2022-07-12 | Globus Medical Inc. | Extended reality headset tool tracking and control |
US11510750B2 (en) | 2020-05-08 | 2022-11-29 | Globus Medical, Inc. | Leveraging two-dimensional digital imaging and communication in medicine imagery in three-dimensional extended reality applications |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4435907A1 (en) * | 1994-10-07 | 1996-04-11 | Lutz Prof Dr Gissmann | Recombinant papilloma virus-like particles contg. L1 or L2 proteins |
WO1996011274A1 (en) * | 1994-10-06 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric papillomavirus-like particles |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122007000018I1 (en) | 1991-07-19 | 2007-05-24 | Univ Queensland | Polynucleotide portion of the HPV16 genome |
GB9207701D0 (en) | 1992-04-08 | 1992-05-27 | Cancer Res Campaign Tech | Papillomavirus e7 protein |
EP0647140B1 (en) | 1992-06-25 | 2007-12-12 | Georgetown University | Papillomavirus vaccines |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
ES2263405T3 (en) * | 1993-03-09 | 2011-04-20 | The University Of Rochester | PRODUCTION OF HUMAN PAPILOMAVIRUS CAPSIDE PROTEIN AND VIRUS TYPE PARTICLES. |
AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
PT809700E (en) * | 1994-10-07 | 2006-09-29 | Univ Loyola Chicago | PARTICLES SIMILAR TO PAPILLOMAVIRUS AND FUSEOUS PROTEINS, AND METHODS FOR THEIR PRODUCTION |
JP3413020B2 (en) * | 1996-07-17 | 2003-06-03 | 株式会社東芝 | Manufacturing method of semiconductor device |
DE19712541C1 (en) | 1997-03-25 | 1998-11-05 | Deutsches Krebsforsch | Papilloma viruses, means for their detection and for the therapy of diseases caused by them |
EP1000157A1 (en) * | 1997-07-03 | 2000-05-17 | University Technology Corporation | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy |
GB2333782B (en) | 1997-08-26 | 2002-09-04 | Nsk Ltd | Method of manufacturing rolling bearings |
US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
-
1997
- 1997-10-06 US US08/944,368 patent/US6228368B1/en not_active Expired - Fee Related
-
1998
- 1998-10-06 DK DK98950930T patent/DK1021547T3/en active
- 1998-10-06 ES ES98950930T patent/ES2280104T3/en not_active Expired - Lifetime
- 1998-10-06 DE DE69841342T patent/DE69841342D1/en not_active Expired - Lifetime
- 1998-10-06 AT AT98950930T patent/ATE349536T1/en active
- 1998-10-06 IL IL13552898A patent/IL135528A0/en active IP Right Grant
- 1998-10-06 ES ES06270010T patent/ES2337492T3/en not_active Expired - Lifetime
- 1998-10-06 TR TR2000/01842T patent/TR200001842T2/en unknown
- 1998-10-06 BR BR9814606-8A patent/BR9814606A/en active Search and Examination
- 1998-10-06 PT PT98950930T patent/PT1021547E/en unknown
- 1998-10-06 EP EP06270010A patent/EP1690941B1/en not_active Expired - Lifetime
- 1998-10-06 DE DE69836753T patent/DE69836753T2/en not_active Expired - Lifetime
- 1998-10-06 WO PCT/US1998/020965 patent/WO1999018220A1/en active Search and Examination
- 1998-10-06 JP JP2000515014A patent/JP4520034B2/en not_active Expired - Fee Related
- 1998-10-06 CZ CZ20001244A patent/CZ302351B6/en not_active IP Right Cessation
- 1998-10-06 EP EP98950930A patent/EP1021547B1/en not_active Expired - Lifetime
- 1998-10-06 CA CA002305382A patent/CA2305382A1/en not_active Abandoned
- 1998-10-06 NZ NZ503830A patent/NZ503830A/en unknown
- 1998-10-06 AT AT06270010T patent/ATE449852T1/en not_active IP Right Cessation
- 1998-10-06 PL PL98339735A patent/PL195332B1/en not_active IP Right Cessation
- 1998-10-06 KR KR1020007003721A patent/KR20010030969A/en not_active Application Discontinuation
- 1998-10-06 HU HU0004360A patent/HU225893B1/en not_active IP Right Cessation
- 1998-10-06 AU AU96846/98A patent/AU9684698A/en not_active Abandoned
-
2000
- 2000-04-06 NO NO20001768A patent/NO328128B1/en not_active IP Right Cessation
- 2000-04-06 IL IL135528A patent/IL135528A/en not_active IP Right Cessation
-
2002
- 2002-04-29 US US10/042,526 patent/US20050031636A1/en not_active Abandoned
-
2006
- 2006-02-21 US US11/358,285 patent/US7371391B2/en not_active Expired - Fee Related
-
2007
- 2007-01-29 CY CY20071100114T patent/CY1105963T1/en unknown
-
2008
- 2008-04-01 IL IL190554A patent/IL190554A0/en unknown
- 2008-04-17 US US12/105,013 patent/US7754430B2/en not_active Expired - Fee Related
-
2009
- 2009-05-04 NO NO20091761A patent/NO20091761L/en not_active Application Discontinuation
- 2009-12-24 JP JP2009292021A patent/JP5296665B2/en not_active Expired - Fee Related
-
2013
- 2013-04-16 JP JP2013085666A patent/JP2013147507A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011274A1 (en) * | 1994-10-06 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric papillomavirus-like particles |
DE4435907A1 (en) * | 1994-10-07 | 1996-04-11 | Lutz Prof Dr Gissmann | Recombinant papilloma virus-like particles contg. L1 or L2 proteins |
Non-Patent Citations (4)
Title |
---|
LI M ET AL.: "Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli", JOURNAL OF VIROLOGY, vol. 71, no. 4, April 1997 (1997-04-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 2988 - 2995, XP002091858 * |
MÜLLER M ET AL.: "Chimeric papillomavirus-like particles", VIROLOGY, vol. 234, no. 1, 21 July 1997 (1997-07-21), ORLANDO US, pages 93 - 111, XP002091857 * |
PAINTSIL J ET AL.: "Carboxy terminus of bovine pappilomavirus type-1 L1 protein is not required for capsid formation", VIROLOGY, vol. 223, no. 1, 1 September 1996 (1996-09-01), ORLANDO US, pages 238 - 244, XP002091859 * |
ROSE R C ET AL: "SEROLOGICAL DIFFERENTIATION OF HUMAN PAPILLOMAVIRUS TYPES 11, 16 AND 18 USING RECOMBINANT VIRUS-LIKE PARTICLES", JOURNAL OF GENERAL VIROLOGY, vol. 75, no. 9, September 1904 (1904-09-01), pages 2445 - 2449, XP000604635 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183377B2 (en) | 1997-05-29 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Human FRP and fragments thereof including methods for using them |
WO1999050424A2 (en) * | 1998-03-27 | 1999-10-07 | Margaret Anne Stanley | Fusion protein comprising a sequence from a major coat protein of a papovavirus |
WO1999050424A3 (en) * | 1998-03-27 | 1999-12-02 | Margaret Anne Stanley | Fusion protein comprising a sequence from a major coat protein of a papovavirus |
WO2000035478A1 (en) * | 1998-12-11 | 2000-06-22 | The University Of Queensland | Treatment of papillomavirus infections |
US7172870B2 (en) | 1998-12-11 | 2007-02-06 | The University Of Queensland Of St. Lucia | Treatment of papillomavirus infections |
US6867033B1 (en) | 1998-12-11 | 2005-03-15 | The University Of Queensland Of St. Lucia | Treatment of papillomavirus infections |
WO2000047722A2 (en) * | 1999-02-11 | 2000-08-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Chimeric virus-like particles or chimeric capsomers from bvp (bovine papilloma virus) |
US6953579B1 (en) | 1999-02-11 | 2005-10-11 | Deutches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Chimeric virus-like particle or chimeric capsomers from BPV |
WO2000047722A3 (en) * | 1999-02-11 | 2002-03-28 | Deutsches Krebsforsch | Chimeric virus-like particles or chimeric capsomers from bvp (bovine papilloma virus) |
WO2000073790A1 (en) * | 1999-06-01 | 2000-12-07 | Medigene Aktiengesellschaft | Test system for in-vitro detection of an antigen-specific immune response |
US6838084B1 (en) | 1999-06-01 | 2005-01-04 | Medigene Aktiengesellschaft | Cytotoxic T-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy |
WO2000073464A1 (en) * | 1999-06-01 | 2000-12-07 | Medigene Aktiengesellschaft | Cytotoxic t-cell epitopes of the papillomavirus l1-protein and use thereof in diagnostics and therapy |
WO2000073335A1 (en) * | 1999-06-01 | 2000-12-07 | Medigene Aktiengesellschaft | Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy |
US6911207B1 (en) | 1999-06-01 | 2005-06-28 | Medigene Aktiengesellschaft | Cytotoxic T-cell epitopes of the papillomavirus L1-protein and use thereof in diagnostics and therapy |
JP2003511010A (en) * | 1999-08-25 | 2003-03-25 | メルク エンド カムパニー インコーポレーテッド | Synthetic human papillomavirus gene optimized for expression in human cells |
JP4799789B2 (en) * | 1999-08-25 | 2011-10-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Synthetic human papillomavirus genes optimized for expression in human cells |
EP1250593A4 (en) * | 1999-12-09 | 2004-03-31 | Medimmune Inc | IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs) |
EP1250593A1 (en) * | 1999-12-09 | 2002-10-23 | Medimmune, Inc. | IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs) |
US8735355B2 (en) | 2000-04-10 | 2014-05-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of use of fragments of secreted frizzled related protein, sFRP |
US7947651B2 (en) | 2000-04-10 | 2011-05-24 | The United States Of America As Represented By The Department Of Health And Human Services | Secreted frizzled related protein, sFRP, fragments and methods of use thereof |
US8158603B2 (en) | 2000-04-10 | 2012-04-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Fragments of secreted frizzled related protein |
US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
WO2002038769A2 (en) * | 2000-11-09 | 2002-05-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
WO2002038769A3 (en) * | 2000-11-09 | 2003-01-09 | Deutsches Krebsforsch | Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
WO2002043757A2 (en) * | 2000-12-01 | 2002-06-06 | Medigene Aktiengesellschaft | Medicament for preventing or treating tumors caused by human papilloma virus type 18 |
WO2002043757A3 (en) * | 2000-12-01 | 2002-10-17 | Medigene Ag | Medicament for preventing or treating tumors caused by human papilloma virus type 18 |
WO2003018623A3 (en) * | 2001-08-31 | 2004-07-29 | Univ Cape Town | Papillomavirus proteins and pharmaceutical compositions |
CN100424094C (en) * | 2001-08-31 | 2008-10-08 | 开普敦大学 | Pharmaceutical compositions, and a method of preparing and isolating said pharmaceutical compositions, and use of said pharmaceutical compositions for prophylactic treatment of lesions and carcinomas |
WO2003018623A2 (en) * | 2001-08-31 | 2003-03-06 | University Of Cape Town | Papillomavirus proteins and pharmaceutical compositions |
US7641896B2 (en) | 2002-07-05 | 2010-01-05 | Folia Biotech Inc. | Adjuvant viral particle |
US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
US8282940B2 (en) | 2002-07-05 | 2012-10-09 | Folia Biotech Inc. | Adjuvant viral particle |
US9339535B2 (en) | 2002-07-05 | 2016-05-17 | Folia Biotech, Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
WO2016026919A1 (en) * | 2014-08-20 | 2016-02-25 | Ruprecht-Karls-Universität Heidelberg | Vaccines and manufacturing methods for treatment and prevention of disease |
WO2021013067A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 6 l1 protein |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6228368B1 (en) | Papilloma virus capsomere formulations and method of use | |
US6352696B1 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
EP0789766A1 (en) | Chimeric papillomavirus-like particles | |
US6649167B2 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
US7182947B2 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
US20030170271A1 (en) | Chimeric papillomavirus-like particles | |
US7494658B2 (en) | Papilloma virus truncated L1 protein and fusion protein constructs | |
AU2003200653B2 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
AU2007201791A1 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
MXPA00003358A (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
CA2201601C (en) | Chimeric papillomavirus-like particles | |
AU717932B2 (en) | Chimeric papillomavirus-like particles | |
MXPA98001583A (en) | Formulations for capsomers vaccines of papillomavirus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 135528 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2305382 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 515014 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/003358 Country of ref document: MX Ref document number: 503830 Country of ref document: NZ Ref document number: PV2000-1244 Country of ref document: CZ Ref document number: 1020007003721 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 96846/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998950930 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/01842 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998950930 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003721 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1244 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007003721 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998950930 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 190554 Country of ref document: IL |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |